Revenue — year-on-year
Matched quarter comparison; actual issuer-reported figures, not a forecast
Watch: Monitor whether this trend persists in subsequent disclosures
Home / Research / Aurobindo Pharma Limited
Revenue — year-on-year
Matched quarter comparison; actual issuer-reported figures, not a forecast
Watch: Monitor whether this trend persists in subsequent disclosures
Matched quarter comparison; actual issuer-reported figures, not a forecast
Watch: Monitor whether this trend persists in subsequent disclosures
Matched quarter comparison; actual issuer-reported figures, not a forecast
Watch: Monitor whether this trend persists in subsequent disclosures
Matched quarter comparison; actual issuer-reported figures, not a forecast
Watch: Monitor whether this trend persists in subsequent disclosures
30-second investment take. Aurobindo's September-quarter revenue and operating profit grew faster than a year ago, supported by US and European formulations, the Lannett acquisition and improving product mix. The opportunity is to turn a broad generic-drug platform into a more differentiated manufacturer; the risk is that acquisitions, regulatory execution and capital spending absorb the incremental earnings. No observed share-price valuation or target is asserted here.
Key takeaways
| Consolidated, ₹ crore | Q2 FY26 | Q2 FY27 | Change |
|---|---|---|---|
| Revenue | 8,286 | 10,263 | +23.9% |
| Operating EBITDA | 1,678 | 2,156 | +28.5% |
| Profit before tax | 1,274 | 1,691 | +32.7% |
| Net profit | 848 | 1,124 | +32.5% |
Why it matters: Profit grew faster than revenue, and reported EBITDA margin improved from approximately 20.3% to 21.0%. This is not evidence that all geographies have equal economics. Monitor next-quarter EBITDA margin and US sales excluding special products or acquisitions. These figures are group consolidated figures, not parent-only earnings.
Reading the operating bridge. Reported sales increased by ₹1,977 crore year on year, while operating EBITDA increased by ₹478 crore. These are differences between disclosed quarters, not estimates of acquisition-adjusted organic growth.
The ₹276 crore increase in net profit cannot be extrapolated mechanically: taxes, financing, depreciation and other income change the conversion from EBITDA to profit. The reported 21.0% EBITDA margin is approximately 0.7 percentage points above the prior-year quarter, but one quarter does not establish a sustainable margin floor.
The next comparable period should show whether incremental US and European sales offset launch, regulatory and integration costs.
Reading the charts. Compare revenue, operating EBITDA and net profit on matched Q2 periods before interpreting the business panels. USA and Europe are geography categories; API is a product category and must not be added to those figures as though it were an independent geographic segment. Watch both absolute growth and margin conversion; a larger revenue bar is not proof of stronger cash generation.
Key takeaways
| Business, ₹ crore | Q2 FY26 | Q2 FY27 | YoY |
|---|---|---|---|
| USA | 3,638 | 4,555 | +25.2% |
| Europe | 2,480 | 3,161 | +27.5% |
| Growth markets | 882 | 1,026 | +16.3% |
| ARV | 325 | 359 | +10.2% |
| Total formulations | 7,325 | 9,102 | +24.2% |
| Beta-lactam API | 687 | 858 | +24.8% |
| Non-beta-lactam API | 273 | 304 | +11.3% |
| Total API | 961 | 1,162 | +20.9% |
API means active pharmaceutical ingredients. Management reports US revenue excluding gRevlimid of US$477 million, compared with US$399 million in Q1 FY27 and US$411 million in Q2 FY26. The US business benefited from Lannett integration, injectable growth and ten product launches, including generic Advair and ADQUEY.
Europe reported €288 million, with management citing 18% constant-currency growth; that is not the same measurement as the rupee-denominated Europe line. Do not add geography and API figures twice.
Why it matters: US product launches and complex generics can improve mix, but acquisition contribution can inflate headline growth. Watch launch persistence, ex-gRevlimid sales, approval-to-commercialisation conversion and product concentration.
Key takeaways
The accepted earnings-call transcript describes completion of Lannett, strengthening US manufacturing and controlled-substance capabilities. Management also describes the A1 Biochem acquisition as part of a small-molecule CRDMO build-out, citing experience across more than 800 development projects.
CRDMO means contract research, development and manufacturing organisation; a project count is not an order book or recognised revenue. The US business launched ten products, filed seven abbreviated new drug applications (ANDAs) and received twelve final approvals in the quarter.
Management highlighted generic Advair, generic QVAR approval, the ADQUEY launch and a Raleigh facility inspection classified VAI (voluntary action indicated).
Why it matters: More complex products may improve competitive positioning, but product filings, approvals and plant readiness do not guarantee sales. Watch realised revenue from newly approved products, USFDA inspection outcomes, integration of acquired facilities and whether biosimilar/biologics manufacturing contributes commercial revenue.
Key takeaways
Management's earnings-call discussion allocates US$47 million of capex to development capabilities and US$42 million to strategic priorities. The company described US$146 million of net cash generation during the quarter.
These dollar figures are issuer management metrics; they must not be silently substituted for statutory consolidated operating cash flow, cash equivalents or net debt. Net cash including investments depends on which investments and borrowings are included.
Finance cost was described as averaging 4.9%, but that is not an enterprise-wide cost of capital.
Why it matters: Capital-intensive complex products need cash conversion. Compare future statutory cash flow, acquisitions, capital spending and debt maturities before treating operating EBITDA as freely distributable cash. The absence of a complete accepted cash/debt bridge in this working manuscript is disclosed rather than filled with invented amounts.
Key takeaways
Management described margin improvement through product mix, procurement and capacity utilisation; the Q2 outcome offers one observation, not a proven multi-year trend. Lannett's contribution needs to be isolated as comparable quarters emerge.
A1 Biochem's project history requires commercial conversion before it can be modelled as recurring revenue. Respiratory approvals and dermatology launches should be tracked against actual prescriptions, supply availability and revenue rather than announcement counts.
The biosimilars and biologics contract-manufacturing initiatives require separate operational evidence before an independent valuation is assigned.
Watch next: Ex-gRevlimid US revenue, reported gross margin, EBITDA margin, new-product commercial sales, facility inspection outcomes, R&D and capex, and acquisition integration costs. No management promise is represented here as independently fulfilled without a subsequent dated observation.
Key takeaways
| Scenario | Evidence-based condition | Investor interpretation |
|---|---|---|
| Bull | New complex US products scale; Europe remains strong; margin improves beyond the reported 21.0% | Better earnings quality and potential multiple support, conditional on cash conversion |
| Base | Core formulations grow, acquired operations integrate gradually and margins remain near the observed range | Operating growth but valuation must reflect execution and capex |
| Bear | Regulatory delays, generic pricing pressure, higher integration costs or weaker cash conversion | Lower profit durability and potentially higher balance-sheet risk |
The scenarios are qualitative, not numerical forecasts. An enterprise-value multiple cannot be converted into a share-price target without net debt, minorities, diluted shares, comparable multiples and a dated market observation.
Those are deliberately not invented. Principal risks include US regulatory inspections, price erosion, product-launch timing, acquired-asset integration, foreign exchange, manufacturing quality, research pipeline conversion and higher capital intensity.
Counterevidence to the positive case would include slowing ex-special-product US revenue, falling margins, negative cash conversion or repeated approval delays.
Scenario sensitivity without a price target. The reported EBITDA margin of approximately 21.0% is the observable starting point. At unchanged quarterly revenue of ₹10,263 crore, a one-percentage-point change in operating EBITDA margin corresponds arithmetically to about ₹102.6 crore of quarterly EBITDA.
This is a sensitivity identity, not a management forecast: it holds sales constant, excludes tax, financing, working capital and capital spending, and does not imply a share value. A stronger scenario requires sustained product-mix gains and cash conversion; a weaker scenario could occur even with sales growth if margins compress or capital intensity increases.
The investor should compare future reported margins and cash flows with these conditions rather than interpreting illustrative cases as targets.
Key takeaways
Primary source A: Aurobindo Pharma Q2 FY27 earnings presentation, dated 5 November 2026, issuer document. Issuer original: . Used for consolidated financials, segment comparisons, capital spending and operating highlights.
Primary source B: Aurobindo Pharma Q2 FY27 earnings-call transcript, call dated 5 November and exchange filing dated 11 November 2026, issuer document. Exchange original: https://nsearchives.nseindia.com/corporate/AUROPHARMA_11112026130442_LtrToSEsTranscriptEarningCall11112026.pdf . Used for management explanations, acquisitions, US launches, regulatory developments and operational intentions.
Reporting period is the quarter ended 30 September 2026. Monetary amounts are ₹ crore unless specifically labelled US dollars or euros. Revenue and profit refer to consolidated group reporting, not the parent company alone. Quarter-on-quarter and year-on-year changes are distinct. No copied source slides, extended quotations or third-party images are included.
Three-point investor guide: First, check whether US revenue excluding exceptional products continues to grow. Second, compare EBITDA improvement with statutory cash generation and capex. Third, require commercial milestones—not merely approvals or development-project counts—before paying for pipeline optionality.
Glossary: EBITDA = earnings before interest, taxes, depreciation and amortisation; API = active pharmaceutical ingredient; ANDA = abbreviated new drug application; CRDMO = contract research, development and manufacturing organisation; PAT = profit after tax; VAI = voluntary action indicated inspection classification.
Disclosure: Based on accepted company disclosures. Some figures and valuations are unavailable. No numerical price target, independent QA certification or claim of statutory audit completion is made.
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.